Get the Stockscreener App
1.62
3.85%
0.06
After Hours:
1.58
-0.04
-2.47%
Prokidney Corp stock is traded at $1.62, with a volume of 359.82K.
It is up +3.85% in the last 24 hours and down -4.42% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
See More
Previous Close:
$1.56
Open:
$1.58
24h Volume:
359.82K
Relative Volume:
0.57
Market Cap:
$204.14M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-3.0258
EPS:
-0.5354
Net Cash Flow:
$-124.27M
1W Performance:
-5.81%
1M Performance:
-4.42%
6M Performance:
-26.36%
1Y Performance:
+0.62%
1-Day Range:
$1.57
$1.64
1-Week Range:
$1.49
$1.76
52-Week Range:
$1.12
$4.44
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
ProKidney to Participate in the Guggenheim Inaugural - GlobeNewswire
ProKidney (PROK) to Present at Guggenheim and Jefferies Healthcare Conferences | PROK Stock News - StockTitan
Head to Head Review: ProKidney (NASDAQ:PROK) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World
ProKidney CEO Bruce Culleton named to Triad Power 50 Five to Watch list - The Business Journals
Suvretta Capital Management's Strategic Acquisition in ProKidney Corp - Yahoo Finance
Reviewing ProKidney (NASDAQ:PROK) and Innate Pharma (NASDAQ:IPHA) - Defense World
We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate - Yahoo Finance
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024 - The Manila Times
ProKidney Announces Five Abstracts Selected for - GlobeNewswire
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024 - Yahoo Finance
Stocks of ProKidney Corp (PROK) are poised to climb above their peers - SETE News
Gaining Ground: ProKidney Corp (PROK) Closes Lower at 1.70, Down -0.58 - The Dwinnex
PROK underperforms with a -1.16 decrease in share price - US Post News
ProKidney Corp (PROK) Becoming More Attractive for Investors - Knox Daily
PROK’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
ProKidney to Participate in the UBS Virtual Organ Restoration Day - GlobeNewswire
ProKidney Corp [PROK] Records 50-Day SMA of $2.2292 - Knox Daily
A History of Outperforming Analyst Forecasts and Beating the Odds: ProKidney Corp (PROK) - SETE News
ProKidney Corp (PROK) deserves deeper analysis - US Post News
Recent Insider Activity Suggests Potential Gains for ProKidney Corp (PROK) - Knox Daily
JPMorgan Chase & Co. Initiates Coverage on ProKidney (NASDAQ:PROK) - MarketBeat
An In-Depth Look at ProKidney Corp Inc. (PROK) Price Performance During Market Crashes - The InvestChronicle
ProKidney Corp (PROK)’s Day in Review: Closing at 1.86, Down by -8.82 - The Dwinnex
JPMorgan starts ProKidney stock coverage with Neutral rating - Investing.com
How does ProKidney Corp (PROK) change from a tortoise to a hare? - SETE News
Insider Selling: Weber Darin J., ProKidney Corp [PROK] Chief Regulatory Officer divested 16,412 shares - Knox Daily
Insiders Re-Evaluate Their US$54.7m Stock Purchase As ProKidney Falls To US$659m - Simply Wall St
ProKidney Corp (PROK) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Is it possible to buy ProKidney Corp(PROK) shares at a good price now? - US Post News
Examining the Potential Price Growth of ProKidney Corp (PROK) - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing ProKidney Corp (PROK)’s Performance - The Dwinnex
ProKidney revises Phase 3 program for lead asset - MSN
Reviewing LadRx (OTCMKTS:CYTR) and ProKidney (NASDAQ:PROK) - Defense World
ProKidney (NASDAQ:PROK) Sees Unusually-High Trading Volume - Defense World
ProKidney executive sells $41,030 in company stock By Investing.com - Investing.com Australia
ProKidney Corp. (NASDAQ:PROK) Insider Darin J. Weber Sells 16,412 Shares - MarketBeat
ProKidney executive sells $41,030 in company stock - Investing.com India
ProKidney (NASDAQ:PROK) Shares Down 6.7% - MarketBeat
Propel Hits 52-Week High on KOHO Link - Baystreet.ca
Propel Holdings Inc. - Baystreet.ca
Wall Street Analyst Initiated ProKidney Corp [PROK]. What else is Wall St. saying - The DBT News
ProKidney Corp [PROK] stock for 2,065 USD was sold by Weber Darin J. - Knox Daily
ProKidney (NASDAQ:PROK) Sees Strong Trading Volume - MarketBeat
PROK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Stocks to Watch: Steelcase, Progyny, America's Car-Mart, Exicure - MarketWatch
ProKidney Corp (PROK) stock analysis: A simple moving average approach - US Post News
Potential Price Increase for ProKidney Corp (PROK) After Recent Insider Activity - Knox Daily
Financial Metrics Exploration: Understanding ProKidney Corp (PROK) Through Ratios - The Dwinnex
ProKidney (NASDAQ:PROK) Shares Gap Down to $2.38 - MarketBeat
ProKidney - The Pharma Letter
ProKidney (NASDAQ:PROK) Shares Down 3.3% - MarketBeat
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):